Copy to clipboard 
ConforMIS (CFMS) announced 2Q18 revenue of US $19.1MM, +3.3% vs. 2Q17, and 1H18 revenue of $38.8MM, -0.5% vs. 1H17.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction Knees | $19.1 | $18.5 | $0.6 | 3.3% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction Knees | $38.8 | $38.9 | -$0.2 | -0.5% |
Revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $16.4 | $32.4 |
| Ex-U.S. | $2.6 | $6.0 |
Knee product sales breakdown:
- iTotal CR, iUni and iDuo $12.9MM, -2%
- iTotal PS $6MM, +23%
Ex-U.S., CFMS continues to face reimbursement battles in Germany and issues with a transition to a distributor model in the U.K., but a new international sales and marketing manager is expected to bring improvements and expansion to other countries, like Australia, which should become visible in 2019.
On the upside, the company performed its first two total hip procedures, including 3D printed patient conforming cutting guides and carrying the same “procedure in a box” concept as the company’s knees, with limited instrumentation trays, etc., to appeal to outpatient facilities. Timing for a complete commercial launch will be announced in 2019.
Leadership also announced a reshuffle in product development, chiefly putting the iUni G3 knee on hold until 1H21 to fast track an iTotal cementless design. A femoral cementless or press fit option is slated for limited launch in early 2020.
The remainder of the launch program looks like this:
2H19
- iTotal G3 cementless for the femur, limited launch
- ConforMIS hip full release
1H20
- iTotal G3 cementless or press fit limited release
2H20
- iTotal G3 full launch
- Second ConforMIS hip stem, limited launch
1H21
- iTotal G3 cementless for femur, full launch
- Tibia option for iTotal G3, limited release
- iUni G3 comes back, limited release
2H21
- Full market launch of second ConforMIS hip stem
Source: ConforMIS, Inc.
ConforMIS (CFMS) announced 2Q18 revenue of US $19.1MM, +3.3% vs. 2Q17, and 1H18 revenue of $38.8MM, -0.5% vs. 1H17.
Q18
Q17
$ Change
% Change
Joint Reconstruction Knees
$19.1
$18.5 ...
ConforMIS (CFMS) announced 2Q18 revenue of US $19.1MM, +3.3% vs. 2Q17, and 1H18 revenue of $38.8MM, -0.5% vs. 1H17.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction Knees | $19.1 | $18.5 | $0.6 | 3.3% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction Knees | $38.8 | $38.9 | -$0.2 | -0.5% |
Revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $16.4 | $32.4 |
| Ex-U.S. | $2.6 | $6.0 |
Knee product sales breakdown:
- iTotal CR, iUni and iDuo $12.9MM, -2%
- iTotal PS $6MM, +23%
Ex-U.S., CFMS continues to face reimbursement battles in Germany and issues with a transition to a distributor model in the U.K., but a new international sales and marketing manager is expected to bring improvements and expansion to other countries, like Australia, which should become visible in 2019.
On the upside, the company performed its first two total hip procedures, including 3D printed patient conforming cutting guides and carrying the same “procedure in a box” concept as the company’s knees, with limited instrumentation trays, etc., to appeal to outpatient facilities. Timing for a complete commercial launch will be announced in 2019.
Leadership also announced a reshuffle in product development, chiefly putting the iUni G3 knee on hold until 1H21 to fast track an iTotal cementless design. A femoral cementless or press fit option is slated for limited launch in early 2020.
The remainder of the launch program looks like this:
2H19
- iTotal G3 cementless for the femur, limited launch
- ConforMIS hip full release
1H20
- iTotal G3 cementless or press fit limited release
2H20
- iTotal G3 full launch
- Second ConforMIS hip stem, limited launch
1H21
- iTotal G3 cementless for femur, full launch
- Tibia option for iTotal G3, limited release
- iUni G3 comes back, limited release
2H21
- Full market launch of second ConforMIS hip stem
Source: ConforMIS, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
